EPIFOAM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Epifoam, and what generic alternatives are available?
Epifoam is a drug marketed by Mylan Speciality Lp and is included in one NDA.
The generic ingredient in EPIFOAM is hydrocortisone acetate; pramoxine hydrochloride. There are sixty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the hydrocortisone acetate; pramoxine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EPIFOAM?
- What are the global sales for EPIFOAM?
- What is Average Wholesale Price for EPIFOAM?
Summary for EPIFOAM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 91 |
Patent Applications: | 3,817 |
DailyMed Link: | EPIFOAM at DailyMed |
Pharmacology for EPIFOAM
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for EPIFOAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Speciality Lp | EPIFOAM | hydrocortisone acetate; pramoxine hydrochloride | AEROSOL, METERED;TOPICAL | 086457-001 | Approved Prior to Jan 1, 1982 | BX | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |